-
Something wrong with this record ?
In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates PMEDAP and PMEG
B. Otová, J. Hrdý, I. Votruba, A. Holý
Anticancer research.
2009 ;
29 (4) :
1295-1302.
Language English Country Greece
Document type Research Support, Non-U.S. Gov't
Persistent link
https://www.medvik.cz/link/bmc11017190
Online
Full text
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
- MeSH
- Adenine analogs & derivatives pharmacology MeSH
- Platelet-Derived Growth Factor genetics metabolism MeSH
- Epidermal Growth Factor genetics metabolism MeSH
- ErbB Receptors genetics metabolism MeSH
- Fibroblast Growth Factor 1 genetics metabolism MeSH
- Guanine analogs & derivatives pharmacology MeSH
- Rats MeSH
- Lymphoma, T-Cell genetics metabolism pathology MeSH
- RNA, Messenger genetics metabolism MeSH
- Organophosphorus Compounds pharmacology MeSH
- Neovascularization, Pathologic metabolism MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Rats, Sprague-Dawley MeSH
- Vascular Endothelial Growth Factor Receptor-1 genetics metabolism MeSH
- Receptor, Fibroblast Growth Factor, Type 1 genetics metabolism MeSH
- Gene Expression Regulation, Neoplastic drug effects MeSH
- Receptor, Platelet-Derived Growth Factor beta genetics metabolism MeSH
- Vascular Endothelial Growth Factor A genetics metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
Acyclic nucleoside phosphonates PMEDAP and PMEG modulate expression of selected proangiogenic genes in SD-lymphoma bearing rats. Antiangiogenic efficacy of PMEDAP is relatively weak and is manifested mainly by down-regulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR detectable 24 hours after treatment. Compound PMEG (an active metabolite of the prodrug GS-9219) down-regulates selected proangiogenic genes EGF, FGF, PDGF, VEGF, EGFR, FGFR, PDGFR and VEGFR much more efficiently. Its antiangiogenic potency persists and is more intensive 48 hours after treatment. Findings show that in vivo antitumour efficacy of both antimitotic acyclic nucleoside phosphonates PMEDAP and PMEG consequently affect the angiogenesis in T-cell lymphoma.
- 000
- 03601naa 2200637 a 4500
- 001
- bmc11017190
- 003
- CZ-PrNML
- 005
- 20221005135031.0
- 008
- 110629s2009 gr e eng||
- 009
- AR
- 035 __
- $a (PubMed)19414378
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Otová, Berta, $d 1943- $7 nlk19990073638
- 245 10
- $a In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates PMEDAP and PMEG / $c B. Otová, J. Hrdý, I. Votruba, A. Holý
- 314 __
- $a Institute of Biology and Medical Genetics, Charles University, Prague, Czech Republic. boto@lf1.cuni.cz
- 520 9_
- $a Acyclic nucleoside phosphonates PMEDAP and PMEG modulate expression of selected proangiogenic genes in SD-lymphoma bearing rats. Antiangiogenic efficacy of PMEDAP is relatively weak and is manifested mainly by down-regulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR detectable 24 hours after treatment. Compound PMEG (an active metabolite of the prodrug GS-9219) down-regulates selected proangiogenic genes EGF, FGF, PDGF, VEGF, EGFR, FGFR, PDGFR and VEGFR much more efficiently. Its antiangiogenic potency persists and is more intensive 48 hours after treatment. Findings show that in vivo antitumour efficacy of both antimitotic acyclic nucleoside phosphonates PMEDAP and PMEG consequently affect the angiogenesis in T-cell lymphoma.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a adenin $x analogy a deriváty $7 D000225
- 650 _2
- $a adenin $x farmakologie $7 D000225
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a epidermální růstový faktor $x genetika $x metabolismus $7 D004815
- 650 _2
- $a fibroblastový růstový faktor 1 $x genetika $x metabolismus $7 D016220
- 650 _2
- $a regulace genové exprese u nádorů $x účinky léků $7 D015972
- 650 _2
- $a guanin $x analogy a deriváty $x farmakologie $7 D006147
- 650 _2
- $a lymfom T-buněčný $x genetika $x metabolismus $x patologie $7 D016399
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a patologická angiogeneze $x metabolismus $7 D009389
- 650 _2
- $a organofosforové sloučeniny $x farmakologie $7 D009943
- 650 _2
- $a destičkový růstový faktor $x genetika $x metabolismus $7 D010982
- 650 _2
- $a messenger RNA $x genetika $7 D012333
- 650 _2
- $a messenger RNA $x metabolismus $7 D012333
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a erbB receptory $x genetika $x metabolismus $7 D066246
- 650 _2
- $a receptor fibroblastových růstových faktorů, typ 1 $x genetika $x metabolismus $7 D051496
- 650 _2
- $a růstový faktor odvozený z trombocytů - receptor beta $x genetika $x metabolismus $7 D020797
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a vaskulární endoteliální růstový faktor A $x genetika $x metabolismus $7 D042461
- 650 _2
- $a receptor 1 pro vaskulární endoteliální růstový faktor $x genetika $x metabolismus $7 D040281
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1#
- $a Hrdý, Jiří. $7 xx0234681
- 700 1_
- $a Votruba, Ivan, $d 1942- $7 xx0030600
- 700 1_
- $a Holý, Antonín, $d 1936-2012 $7 jn20000401004
- 773 0_
- $t Anticancer Research $w MED00000478 $g Roč. 29, č. 4 (2009), s. 1295-1302 $x 0250-7005
- 856 41
- $u https://ar.iiarjournals.org/content/29/4/1295 $y plný text volně přístupný
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110720102837 $b ABA008
- 991 __
- $a 20221005135026 $b ABA008
- 999 __
- $a ok $b bmc $g 864193 $s 726988
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00000478 $b 29 $c 4 $d 1295-1302 $i 0250-7005 $m Anticancer research $n Anticancer Res
- LZP __
- $a 2011-3B09/BBjvme
